Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
- PMID: 27232929
- PMCID: PMC4916303
- DOI: 10.1038/bcj.2016.34
Busulfan for the treatment of myeloproliferative neoplasms: the Mayo Clinic experience
References
-
- Brodsky I. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol 1998; 21: 105–106. - PubMed
-
- Haanen C, Peetermans N, Cauchie C, Michel J, Strijckmans P, Mathe G et al. Treatment of polycythemia vera by radiophosphorous or busulphan: a randomized trial. "Leukemia and Hematosarcoma" Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Br J Cancer 1981; 44: 75–80. - PMC - PubMed
-
- Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132–143. - PubMed
-
- Hehlmann R, Heimpel H, Hasford J, Kolb HJ, Pralle H, Hossfeld DK et al. Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. The German CML Study Group. Blood 1993; 82: 398–407. - PubMed
-
- Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Cea F. Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 2005; 105: 2664–2670. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
